Canna Law Blog

NOVEMBER 27, 2021

Notwithstanding its dubious distinction as a Schedule I drug, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. regulators to launch a clinical program to study the use of DMT for the treatment of stroke-related dysfunction.

Therapy 87

Therapy Clinical Trials DEA Microdosing 87

The Cannigma

DECEMBER 12, 2022

And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. What is microdosing? How do psychedelics work?

History 119

History Microdosing Research and Development Clinical Trials 119

The Cannigma

JUNE 24, 2021

While many health conditions can be treated with more traditional pharmaceuticals, plant-based products may be a safer and healthier option – or at least a safe health supplement. These natural alternatives may also be effective as part of a daily “microdosing” regiment. Part of a natural, alternative lifestyle.

CBD 75

CBD Microdosing Edibles Sleep 75

Cannabis Law Report

SEPTEMBER 10, 2019

” Here’s some of the topics covered in their latest newsletter. Forbes reported on Hopkins researchers’ recommendation that, if psilocybin should clear Phase III clinical trials, the FDA should reclassify it from a Schedule I to a Schedule IV drug. Psychedelic Research News.

Research and Development 45

Research and Development Microdosing Clinical Trials Decriminalization 45

CannaMD

OCTOBER 7, 2019

Besides going against all the classic “munchies/stoner” stereotypes, this finding is especially puzzling as cannabis is often used to increase weight gain in patients with medical conditions such as HIV/AIDS and cancer. So why are medical marijuana patients gaining weight when they need to, but losing weight when they don’t?

Marijuana 105

Marijuana Cannabinoids Patients Conditions 105

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Harris has written a variety of books that touch on the topics of consciousness, spirituality, and psychedelics. Rick Doblin, Ph.D,

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51